Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy.
Oncoimmunology
; 12(1): 2275333, 2023.
Article
in En
| MEDLINE
| ID: mdl-37937212
ABSTRACT
Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunotherapy
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Oncoimmunology
Year:
2023
Document type:
Article
Affiliation country: